Insight Innovation: The Risky Bet on the First Cancer Vaccine
Skin cancer could soon be fought using the same principle that was used to tame the coronavirus. Moderna and Merck are reporting success with an mRNA vaccine. However, there are hurdles.
Moderna has announced positive test results for an innovative skin cancer vaccine developed in partnership with Merck & Co. The vaccine uses mRNA technology and has shown promise in a large, approval-relevant study. This marks a significant scientific breakthrough, with potential for the medication to be on the market as early as 2027.
Analysts expect billions in sales, and experts believe this could pave the way for using a similar approach to combat cancer as was used to combat COVID-19. Moderna CEO Stéphane Bancel is leading the company's efforts in this area.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
